Discover CME, tools, and guideline-focused education to improve your knowledge - and patient outcomes.
IBD Beyond Symptoms: What Community GIs Need to Know
David T. Rubin, MD
Ugonna Iroku, MD, MHS
Targeting Inflammation in IBD: Localized vs Systemic Strategies
Michael Dolinger, MD, MBA
Putting It All Together: Challenges Addressed
Understanding the Microbiome’s Role in IBD Management
Florence Odufalu, MD
Clear Skin, Clear Path: Transforming Psoriasis Care with Durable Biologic and Oral IL-23 Innovations
June 12, 2026 Denver, Colorado
Retina Rumble: Debating Modern Treatment Options
Roger A. Goldberg, MD, MBA
Christina Y. Weng, MD, MBA, FASRS
Yasha S. Modi, MD
Incorporating Novel Muscarinic Agents for Schizophrenia Into Clinical Practice: Overcoming Clinical Inertia
May 28, 2026 Miami Beach, Florida
The Future of HNSCC: Aligning Teams, Transforming Care
Ravindra Uppaluri, MD, PhD
Nancy Lee, MD, FASTRO
Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
Enriqueta Felip, MD
Kristi Orbaugh, MSN, RNP, AOCN
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
May 30, 2026 Chicago, Illinois
IBD Masterclass: Foundations of Pathophysiology and Targeted Therapy
Sharon Dudley-Brown, PhD, FNP-BC, FAAN, FAANP
Beyond Biology: Environmental and Lifestyle Influences in IBD
Genetic Susceptibility in IBD: From Risk Genes to Clinical Impact
Seeing the Invisible: Radiologic Precision to Enable Early Intervention in Bronchiectasis
May 13, 2026
06:00 PM - 07:00 PM ET
The IgG Clock: Redose Using IgG Kinetics
Christyn Edmundson, MD
Gil I. Wolfe MD, FAAN
Shared Goals, Shared Gains: Align With Patient Preferences
Turning Flares Into Function: Flag Uncontrolled Disease
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
Minimal By Design: Define MSE Endpoints
When to Begin FcRn: Initiation Criteria, Key Evidence
Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
September 30, 2026 Orlando, Florida
Escalate With Intention: Stepwise, Target-Anchored Moves
FcRn: Same Class, Different Paths—Spot Agent Differentiators
Treat. Target. Transform: Applying Treat-to-Target Principles in the Management of Generalized Myasthenia Gravis (gMG)
Shifting the Script: Personalizing Overactive Bladder Treatment in Complex Patients
David Staskin, MD
Matt T. Rosenberg, MD
Kennedy Koebbe, MSN, RN
Inside the 4 Hits: Targeting APRIL to Change the Course of IgAN
Richard Lafayette, MD, FACP
Dana Rizk, MD
Hong Zhang
Suzuki Yusuke, MD, PhD
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.